Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group.
Palassini E, Baldi GG, Sulfaro S, Barisella M, Bianchi G, Campanacci D, Fiore M, Gambarotti M, Gennaro M, Morosi C, Navarria F, Palmerini E, Sangalli C, Sbaraglia M, Trama A, Asaftei S, Badalamenti G, Bertulli R, Bertuzzi AF, Biagini R, Bonadonna A, Brunello A, Callegaro D, Cananzi F, Cianchetti M, Collini P, Comandini D, Curcio A, D'Ambrosio L, De Pas T, Dei Tos AP, Ferraresi V, Ferrari A, Franchi A, Frezza AM, Fumagalli E, Ghilli M, Greto D, Grignani G, Guida M, Ibrahim T, Krengli M, Luksch R, Marrari A, Mastore M, Merlini A, Milano GM, Navarria P, Pantaleo MA, Parafioriti A, Pellegrini I, Pennacchioli E, Rastrelli M, Setola E, Tafuto S, Turano S, Valeri S, Vincenzi B, Vitolo V, Ivanescu A, Paloschi F, Casali PG, Gronchi A, Stacchiotti S. Palassini E, et al. Among authors: merlini a. Cancer Treat Rev. 2024 May;126:102722. doi: 10.1016/j.ctrv.2024.102722. Epub 2024 Mar 30. Cancer Treat Rev. 2024. PMID: 38604052 Free article. Review.
Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group.
D'Ambrosio L, Fumagalli E, De Pas TM, Nannini M, Bertuzzi A, Carpano S, Boglione A, Buonadonna A, Comandini D, Gasperoni S, Vincenzi B, Brunello A, Badalamenti G, Maccaroni E, Baldi GG, Merlini A, Mogavero A, Ligorio F, Pennacchioli E, Conforti F, Manessi G, Aliberti S, Tolomeo F, Fiore M, Sbaraglia M, Dei Tos AP, Stacchiotti S, Pantaleo MA, Gronchi A, Grignani G; Italian Sarcoma Group. D'Ambrosio L, et al. Among authors: merlini a. JAMA Netw Open. 2023 Nov 1;6(11):e2341522. doi: 10.1001/jamanetworkopen.2023.41522. JAMA Netw Open. 2023. PMID: 37930700 Free PMC article.
Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study.
Conforti F, Gronchi A, Penel N, Jones RL, Broto JM, Sala I, Bagnardi V, Napolitano A, Pala L, Pennacchioli E, Catania C, Queirolo P, Grigani G, Merlini A, Stacchiotti S, Comandone A, Vincenzi B, Quagliuolo V, Bertuzzi A, Boglione A, Palassini E, Baldi GG, Blay JY, Ryckewaert T, Toulmonde M, Italiano A, Le Cesne A, Ray-Coquard I, Cruz J, Hernández-León CN, Trufero JM, da Silva Moura D, Muñiz NH, De Pas T. Conforti F, et al. Among authors: merlini a. Eur J Cancer. 2022 Aug;171:183-192. doi: 10.1016/j.ejca.2022.04.030. Epub 2022 Jun 18. Eur J Cancer. 2022. PMID: 35728378
Corrigendum to 'Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study' [Eur J Cancer 171 (2022) 183-192].
Conforti F, Gronchi A, Penel N, Jones RL, Broto JM, Sala I, Bagnardi V, Napolitano A, Pala L, Pennacchioli E, Catania C, Queirolo P, Grigani G, Merlini A, Stacchiotti S, Comandone A, Vincenzi B, Quagliuolo V, Bertuzzi A, Boglione A, Palassini E, Baldi GG, Blay JY, Ryckewaert T, Toulmonde M, Italiano A, Le Cesne A, Ray-Coquard I, Cruz J, Hernández-León CN, Trufero JM, da Silva Moura D, Muñiz NH, De Pas T. Conforti F, et al. Among authors: merlini a. Eur J Cancer. 2023 May;184:197-198. doi: 10.1016/j.ejca.2022.11.027. Epub 2023 Mar 10. Eur J Cancer. 2023. PMID: 36907702 No abstract available.
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study.
Nannini M, Rizzo A, Nigro MC, Vincenzi B, Mazzocca A, Grignani G, Merlini A, D'Ambrosio L, Tolomeo F, Badalamenti G, Incorvaia L, Bonasera A, Fumagalli E, Miliziano D, Ligorio F, Brunello A, Chiusole B, Gasperoni S, Novelli M, Pantaleo MA. Nannini M, et al. Among authors: merlini a. ESMO Open. 2021 Aug;6(4):100222. doi: 10.1016/j.esmoop.2021.100222. Epub 2021 Aug 2. ESMO Open. 2021. PMID: 34352702 Free PMC article.
Delving into PARP inhibition from bench to bedside and back.
Grignani G, Merlini A, Sangiolo D, D'Ambrosio L, Pignochino Y. Grignani G, et al. Among authors: merlini a. Pharmacol Ther. 2020 Feb;206:107446. doi: 10.1016/j.pharmthera.2019.107446. Epub 2019 Nov 19. Pharmacol Ther. 2020. PMID: 31756364 Review.
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination.
Merlini A, Centomo ML, Ferrero G, Chiabotto G, Miglio U, Berrino E, Giordano G, Brusco S, Pisacane A, Maldi E, Sarotto I, Capozzi F, Lano C, Isella C, Crisafulli G, Aglietta M, Dei Tos AP, Sbaraglia M, Sangiolo D, D'Ambrosio L, Bardelli A, Pignochino Y, Grignani G. Merlini A, et al. Front Oncol. 2022 Aug 30;12:844250. doi: 10.3389/fonc.2022.844250. eCollection 2022. Front Oncol. 2022. PMID: 36110934 Free PMC article.
85 results